// App-Quantinova.ai

P134 : Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from two Phase 3 Studies

Researchers

Presenter

  • Xenofon Baraliakos

Principal Investigators

  • Roberto Ranza

  • Andrew Ostor

  • Francesco Ciccia

  • Laura C Coates

  • Simona Rednic

  • Jessica Walsh

  • Tianming Gao

  • Apinya Lertratanakul

  • In-Ho Song

  • Fabiana Fabiana Ganz

  • Kevin Douglas

  • Atul Deodhar

Medical Centers

  • Rheumatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy

  • Nuffield Department of Orthopaedics, Botnar Research Centre, Oxford, United Kingdom

  • George E. Wahlen Department of Veterans Affairs Medical Center, University of Utah School of Medicine, Salt Lake City, UT

  • Pediatrics, Oregon Health & Science University, Portland, OR

  • Matematica, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil

  • Department of Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy and County Hospital, Cluj, Romania

  • Rheumatology, Cabrini Hospital & Emeritus Research, Melbourne, Australia

  • Rheumazentrum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany

  • Rheumatology, AbbVie, North Chicago, IL

Locations

  • Italy

  • Romania

  • United Kingdom

  • Australia

  • United States

  • Germany

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved